Enfusion (ENFN) to Release Earnings on Tuesday

Enfusion (NYSE:ENFN) is projected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $54.39 million for the quarter.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Price Performance

Shares of NYSE:ENFN opened at $11.24 on Friday. The company has a market cap of $1.44 billion, a P/E ratio of 280.95, a PEG ratio of 1.85 and a beta of 0.95. Enfusion has a 1 year low of $7.83 and a 1 year high of $11.80. The stock’s fifty day moving average price is $10.98 and its 200-day moving average price is $9.89.

Insider Buying and Selling at Enfusion

In other Enfusion news, insider Bronwen Bastone sold 3,126 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares in the company, valued at $2,524,937.50. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Neal Pawar sold 2,769 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the sale, the chief operating officer now owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 101,789 shares of company stock valued at $1,127,449. 36.44% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ENFN shares. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus increased their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Enfusion currently has an average rating of “Hold” and an average target price of $11.13.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.